PRDX6

Across TCGA pan-cancer cohorts, PRDX6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRDX6 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PRDX6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRDX6 expression acts as an unfavorable survival marker.

KIRP, BLCA, and LUSC are the cancer types where PRDX6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.141	0.904	<.001	36	view →
BLCA	OS	Median	All	0.153	0.720	<.001	27	view →
LUSC	DFS	Median	II,III,IV	0.198	0.719	.005	12	view →
LUAD	OS	Median	All	0.296	0.685	.017	9	view →
READ	DFS	Median	IV	0.255	0.628	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRDX6–KIRP (OS)

Open the KIRP breakdown →